HC Wainwright Forecasts Strong Price Appreciation for uniQure (NASDAQ:QURE) Stock

uniQure (NASDAQ:QURE) had its price objective upped by HC Wainwright from $25.00 to $70.00 in a report issued on Monday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

Other equities analysts have also recently issued reports about the company. StockNews.com raised uniQure to a “sell” rating in a report on Wednesday, December 11th. The Goldman Sachs Group boosted their target price on shares of uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 12th. Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and raised their price target for the stock from $20.00 to $52.00 in a research note on Tuesday, December 10th. Leerink Partners lifted their price target on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. Finally, Wells Fargo & Company raised shares of uniQure from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, uniQure has an average rating of “Moderate Buy” and an average target price of $40.00.

uniQure Price Performance

Shares of NASDAQ QURE opened at $15.80 on Monday. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The company’s 50-day moving average price is $12.93 and its 200 day moving average price is $8.74. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18. The stock has a market cap of $770.09 million, a price-to-earnings ratio of -3.19 and a beta of 0.41.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The business had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. As a group, research analysts forecast that uniQure will post -3.74 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the transaction, the chief executive officer now directly owns 597,915 shares in the company, valued at $4,562,091.45. This trade represents a 0.57 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 4.74% of the company’s stock.

Institutional Trading of uniQure

A number of institutional investors and hedge funds have recently bought and sold shares of the business. RTW Investments LP acquired a new position in uniQure during the third quarter valued at approximately $49,000. China Universal Asset Management Co. Ltd. raised its stake in shares of uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 3,663 shares during the period. Atria Investments Inc acquired a new position in shares of uniQure during the 3rd quarter valued at $53,000. Quarry LP acquired a new position in shares of uniQure during the 3rd quarter valued at $58,000. Finally, Vanguard Personalized Indexing Management LLC boosted its position in uniQure by 21.0% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,306 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.